Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir
among viral isolates from protease inhibitor-experienced patients.
One of the aims of the present study was to investigate whether the expression of the anti-angiogenic VEGF splice variant; VEGF165b could be altered in cancer cervical and normal cervical cells exposed to lopinavir
and curcumin, individually and/or in combination.
En la poblacion bajo estudio, las siguientes categorias de tratamiento fueron clasificadas desde las mas utilizadas a las menos utilizadas: (1) Efavirenz mas Lamivudina + Zidovudina (29.5%), (2) Lamivudina + Zidovudina + Ritonavir + Lopinavir
(14%), (3) Abacavir + Lamivudina + Ritonavir + Lopinavir
(5.4%), (4) Abacavir + Lamivudina + Efavirenz (5.4%) y (5) Atazanavir + Lamivudina + Ritonavir + Zidovudina (4.7%).
Paralytic ileus possibly associated with interaction between ritonavir/ lopinavir
Now you turn to the DAD decoder and add that this same patient took lopinavir
for 3 years and is still taking lopinavir
Infants in the lopinavir
group had levels of the drug in their hair that measured 87 percent of the levels found in their mothers' hair.
In studies in healthy volunteers, severe hepatotoxicity was seen when rifampicin was administered in combination with ritonavir-boosted lopinavir
and saquinavir, particularly in participants initiated on rifampicin before the boosted protease inhibitor.
"In addition we were also able to show that lopinavir
kills these HPV-infected cells by reactivating a well-known antiviral system that is suppressed by HPV." To be effective as a treatment, the drug would have to be administered in doses that are taken by HIV patients 10 to 15 times.
Dr Ian Hampson, of the University of Manchester's School of Medicine, said: "We have now found lopinavir
selectively kills HPV-infected, non-cancerous cells, while leaving healthy cells relatively unaffected."
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir
. Antimicrob Agents Chemother 2007; 51 : 3075-80.
Liver toxicity of lopinavir
containing regimens in HIV-infected patients with or without hepatitis C coinfection.